Aeterna Zentaris Announces Election of Directors at 2016 Shareholders' Meeting

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health, today announced the results of the vote on directors held at its 2016 annual meeting of shareholders held earlier today on May 10, 2016. Each of the director nominees proposed by management for election was elected as director, without a vote by ballot being conducted. The Company received proxies with regard to voting on the six directors nominated for election as set forth in the table below:

Name of Nominee

Votes For

%

Votes Withheld

%

        
      
      
        
          Michael Cardiff
        
        
           
        
        
           
        
        
          1,254,909
        
        
           
        
        
          88.53
        
        
           
        
        
          162,647
        
        
          11.47
        
      
      
        
          David A. Dodd
        
        
           
        
        
           
        
        
          1,187,024
        
        
           
        
        
          83.74
        
        
           
        
        
          230,532
        
        
          16.26
        
      
      
        
          Carolyn Egbert
        
        
           
        
        
           
        
        
          1,268,485
        
        
           
        
        
          89.48
        
        
           
        
        
          149,071
        
        
          10.52
        
      
      
        
          Juergen Ernst
        
        
           
        
        
           
        
        
          1,266,892
        
        
           
        
        
          89.37
        
        
           
        
        
          150,664
        
        
          10.63
        
      
      
        
          Gérard Limoges
        
        
           
        
        
           
        
        
          1,268,600
        
        
           
        
        
          89.49
        
        
           
        
        
          148,956
        
        
          10.51
        
      
      
        
          Ken Newport
        
        
           
        
        
           
        
        
          1,254,215
        
        
           
        
        
          88.48
        
        
           
        
        
          163,341
        
        
          11.52
        
      
    
    

All other matters at the shareholders' meeting were also approved by shareholders.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition or license of products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160510006447/en/

Aeterna Zentaris Inc.Philip A. TheodoreSenior Vice [e-mail]